Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study
| Autor: | Sahil Nohria, Omesh Goyal, Ajit Sood, Prerna Goyal, Jaskirat Kaur, Sarit Sharma, Rajoo Singh Chhina |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Agonist
Male medicine.medical_specialty medicine.drug_class Diseases Disease Gastroenterology Article 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Endocrinology Medical research Non-alcoholic Fatty Liver Disease Internal medicine medicine Humans Pyrroles Aspartate Aminotransferases Prospective Studies Dyslipidemias Multidisciplinary biology Phenylpropionates business.industry Fatty liver Saroglitazar Health care Alanine Transaminase Middle Aged medicine.disease chemistry Alanine transaminase Diabetes Mellitus Type 2 Liver 030220 oncology & carcinogenesis biology.protein Regression Analysis 030211 gastroenterology & hepatology Observational study Female Glycated hemoglobin business Body mass index medicine.drug |
| Zdroj: | Scientific Reports |
| ISSN: | 2045-2322 |
| Popis: | Saroglitazar, a dual peroxisome proliferator activated receptor α/γ agonist, approved for diabetic dyslipidemia (DD), is potential therapeutic option for non-alcoholic fatty liver disease (NAFLD). This prospective, observational, real-world study aimed to determine efficacy and safety of Saroglitazar in patients with NAFLD and DD. We included patients with DD and NAFLD who received Saroglitazar 4 mg once daily for 24 weeks. Blood investigations, liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) (FibroScan) were compared at baseline and 24 weeks. Of 163 patients screened, 107 were included, and 101 completed 24 weeks treatment (mean age 50.4 ± 12.3 years, 78.5% males, mean body mass index 28.8 ± 4.2). After 24 weeks, alanine transaminase (ALT) reduced significantly from 94 (47–122) to 39 (31–49) (p p p = 0.0261). CAP, glycated hemoglobin and lipid parameters also improved significantly. On linear regression, there was significant association between percent change in ALT and AST with TG reduction after treatment (p = 0.024 and 0.037 respectively).We conclude that Saroglitazar leads to significant improvement in transaminases, LSM, and CAP in NAFLD patients with DD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|